🇰🇪

Moderna had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines.
The move is in line with Moderna’s strategy of resizing its manufacturing network to cut costs, even as it aims to spend around $4.5 billion this year in research and development of several new vaccines, including for cancer and respiratory syncytial virus (RSV).

The company had said in 2022 that it would invest about $500 million in the Kenya facility and supply as many as 500 million doses of its mRNA vaccines to Africa each year.

It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023.

However, Moderna has not received any vaccine orders for Africa since 2022 amid waning demand globally, the company said.
The drugmaker said it had taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from Africa.

#Kenya